Invention Grant
- Patent Title: Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
-
Application No.: US14956242Application Date: 2015-12-01
-
Publication No.: US09708596B2Publication Date: 2017-07-18
- Inventor: Peter Sebo , Adriana Osickova , Jiri Masin , Catherine Fayolle , Jan Krusek , Marek Basler , Claude Leclerc , Radim Osicka
- Applicant: INSTITUT PASTEUR , INSTITUTE OF MICROBIOLOGY OF THE ASCR, V.V.I. , INSTITUTE OF PHYSIOLOGY OF THE ASCR, V.V.I.
- Applicant Address: FR Paris CZ Prague CZ Prague
- Assignee: INSTITUT PASTEUR,INSTITUTE OF MICROBIOLOGY OF THE ASCR, V.V.I.,INSTITUTE OF PHYSIOLOGY OF THE ASCR, V.V.I.
- Current Assignee: INSTITUT PASTEUR,INSTITUTE OF MICROBIOLOGY OF THE ASCR, V.V.I.,INSTITUTE OF PHYSIOLOGY OF THE ASCR, V.V.I.
- Current Assignee Address: FR Paris CZ Prague CZ Prague
- Agency: Arrigo, Lee & Guttman LLP
- Priority: EP09155929 20090323
- Main IPC: C12N9/88
- IPC: C12N9/88
Abstract:
The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. The mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.
Public/Granted literature
Information query
